Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.71 |
| ▸ | MTOR | P42345 | 10/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.51 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.51 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14052023 | 0.87 | PIK3CA (0.72) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4437396 | 0.83 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4556013 | 0.83 | PIK3CA (0.79) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4446854 | 0.82 | PIK3CA (0.65) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4437370 | 0.79 | PIK3CA (0.73) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4563843 | 0.79 | PIK3CA (0.72) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4435407 | 0.78 | PIK3CA (0.72) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4438242 | 0.77 | PIK3CA (0.66) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4439824 | 0.77 | PIK3CA (0.69) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4438146 | 0.77 | PIK3CA (0.66) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885MTOR 11/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.